|
Status |
Public on Oct 25, 2017 |
Title |
AML 31 DAY 3 |
Sample type |
RNA |
|
|
Source name |
Leukemic blasts
|
Organism |
Homo sapiens |
Characteristics |
cell type: Leukemic blasts disease state: Acute myeloid leukemia gender: M age: 68 aml status: Secondary (CMF) fab: M4 cd34: Pos cd117: Pos cytogenetics: Normal
|
Extracted molecule |
total RNA |
Extraction protocol |
RNA isolation was performed according to QIAgen's instructions in the RNeasy with DNase treatment protocol for the QIAcube.
|
Label |
biotin
|
Label protocol |
Biotinylated cRNA were prepared with the Illumina TotalPrep-96 RNA Amplification Kit from Thermo Fisher Scientific
|
|
|
Hybridization protocol |
Standard Illumina hybridization protocol
|
Scan protocol |
Standard Illumina scanning protocol
|
Data processing |
Data were quantile-normalised (http://www.molmine.com/magma/loading/illumina.html) using J-Express version 2012 (http://jexpress.bioinfo.no/site/)
|
|
|
Submission date |
Oct 24, 2017 |
Last update date |
Oct 25, 2017 |
Contact name |
Hakon Reikvam |
E-mail(s) |
Hakon.Reikvam@uib.no
|
Phone |
+4755585408
|
Organization name |
University of Bergen
|
Department |
Department of Clinical Science
|
Street address |
Jonas Lies vei 65
|
City |
Bergen |
ZIP/Postal code |
5021 |
Country |
Norway |
|
|
Platform ID |
GPL10558 |
Series (1) |
GSE106096 |
Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia |
|